Search Results

Vect-Horus announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26.

VECT-HORUS today announced the appointment Pr. Xavier Declèves to its scientific advisory board (SAB).

Vect-Horus today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).

Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S.

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer.

RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).

Vect-Horus announced the appointment of Pr. Frédéric Matonti to its scientific advisory board.

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced the signing of a collaboration agreement with CERIMED (European Centre for Research in Medical Imaging) to support the preclinical development of VECT-HORUS’ theragnostic agents.

MDimune Inc. and Vect-Horus are please to announce today the signing of a Research Collaboration Agreement.

Horus Pharma, an independent French company leading player in ophthalmology, strengthens its international presence with the signature of eight distribution agreements – covering Romania, Portugal, Croatia, Turkey, Algeria, Qatar, Ireland and Bosnia – taking its total number of collaborations to 19.